These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19616703)

  • 1. Phase 0 trials: a platform for drug development?
    Lancet; 2009 Jul; 374(9685):176. PubMed ID: 19616703
    [No Abstract]   [Full Text] [Related]  

  • 2. The exploratory IND.
    Mills G
    J Nucl Med; 2008 Jun; 49(6):45N-47N. PubMed ID: 18511824
    [No Abstract]   [Full Text] [Related]  

  • 3. Innovative early development regulatory approaches: expIND, expCTA, microdosing.
    Robinson WT
    Clin Pharmacol Ther; 2008 Feb; 83(2):358-60. PubMed ID: 18091759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of eINDs for evaluation of multiple related PET amyloid plaque imaging agents.
    Skovronsky D
    J Nucl Med; 2008 Jun; 49(6):47N-48N. PubMed ID: 18511825
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulatory considerations for preclinical development of anticancer drugs.
    DeGeorge JJ; Ahn CH; Andrews PA; Brower ME; Giorgio DW; Goheer MA; Lee-Ham DY; McGuinn WD; Schmidt W; Sun CJ; Tripathi SC
    Cancer Chemother Pharmacol; 1998; 41(3):173-85. PubMed ID: 9443633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of exploratory investigational new drugs for translating radiopharmaceuticals into first-in-human studies.
    Schwarz SW; Oyama R
    J Nucl Med; 2015 Apr; 56(4):497-500. PubMed ID: 25766895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique/major human metabolites: why, how, and when to test for safety in animals.
    Luffer-Atlas D
    Drug Metab Rev; 2008; 40(3):447-63. PubMed ID: 18642142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanics of the Food and Drug Administration's Form 1571: investigational new drug application.
    Novack G
    Retina; 2005 Dec; 25(8 Suppl):S96-S97. PubMed ID: 16374362
    [No Abstract]   [Full Text] [Related]  

  • 10. The do's and don'ts of preclinical development.
    Graffeo A
    Biotechnology (N Y); 1994 Sep; 12(9):865-9. PubMed ID: 7765226
    [No Abstract]   [Full Text] [Related]  

  • 11. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trials and tribulations: a primer on successfully navigating the waters of the Food and Drug Administration.
    Feinsod M; Chambers WA
    Ophthalmology; 2004 Oct; 111(10):1801-6. PubMed ID: 15465539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Sep; 75(188):59935-63. PubMed ID: 20879180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.
    van Gerven J; Bonelli M
    Br J Clin Pharmacol; 2018 Jul; 84(7):1401-1409. PubMed ID: 29451320
    [No Abstract]   [Full Text] [Related]  

  • 16. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
    Prowell T
    Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs.
    Black LE; Degeorge JJ; Cavagnaro JA; Jordan A; Ahn CH
    Antisense Res Dev; 1993; 3(4):399-404. PubMed ID: 8155981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric drug development in anesthesiology: an FDA perspective.
    Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
    Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
    [No Abstract]   [Full Text] [Related]  

  • 19. Ethnic differences in pharmacokinetics in new drug applications and approved doses in Japan.
    Fukunaga S; Kusama M; Arnold FL; Ono S
    J Clin Pharmacol; 2011 Aug; 51(8):1237-40. PubMed ID: 21209235
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.